Value Added Dasatinib

Value Added Dasatinib
Product Description

Value added Dasatinib (Teaser attached) 

  •  Dasatinib is a targeted therapy used to treat certain cases of chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL) 
  •  Current available products on the market are not completely absorbed by those patients taking Antacids, PPI’s (Omerpazole) or with high stomach pH level (achlorhydria) 
  •  The prescriber or patient does not need to worry about consumption of Omeprazole (PPI) when taking Zentiva‘s Dasatinib, which has been proven to deliver clinically effective dose with or without PPI (Omeprazole). 
  •  The product is available for Co-development for US and for out licensing in selected EU countries. 
  •  For more details contact  Vaibhav Sharma, Head of Value added products ([email protected] )

Zentiva

  • CZ
  • 2019
    On CPHI since

Zentiva

  • CZ
  • 2019
    On CPHI since

More Products from Zentiva (3)

  • Zent2U - Zentiva B2B Platform

    Product Zent2U - Zentiva B2B Platform

    Zent2U (www.zent2u.com) is a B2B platform of Zentiva established in 2019 to collaborate with customers on:

    - Licensing-out dossiers developed by Zentiva

    - Co-development opportunities by co-financing Zentiva's products in development

    - CMO services by Zentiva in production ...
  • Value Added Abiraterone

    Product Value Added Abiraterone

    Value added Abiraterone  •  Abiraterone is a medication used to treat prostate cancer  •  The recommended dose is 1,000 mg as a single daily dose that must not be taken with food.  •  Administering  with food results up to a 10-fold (AUC) and up to a 17-fo...
  • Innovative combination Finasteride + Tadalafil

    Product Innovative combination Finasteride + Tadalafil

    Innovative combination Finasteride + Tadalafil   • Both products individually are approved for BPH (Benign prostatic hyperplasia) in Europe.  • The most frequent adverse reactions are impotence and decreased libido in Finasteride. The benefit of Tadalafil is early onset of the...

Zentiva resources (2)